ΔTRAC CAR ΔB2M HLAE

ΔTRAC CAR ΔB2M HLAE is an allogeneic, immune-evasive chimeric antigen receptor (CAR) T-cell therapy developed by Cellectis. The therapy is engineered using TALEN-mediated gene editing and adeno-associated virus (AAV) vectors to create a "universal" donor product. It features three key genetic modifications: the knockout of the T-cell receptor alpha constant (TRAC) locus to prevent graft-versus-host disease (GvHD); the knockout of the beta-2 microglobulin (B2M) gene to eliminate surface HLA Class I expression and evade host T-cell rejection; and the engineered expression of HLA-E on the cell surface to inhibit natural killer (NK) cell-mediated lysis. This multi-layered approach is designed to enhance the persistence and efficacy of off-the-shelf CAR T-cells in treating hematological malignancies, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).

Other names

immune-evasive universal CAR T-cell therapy